Skip to main content

Table 1 Characteristics of the 30 patients with Gram-negative VAP*

From: Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia

Parameter Value
Age (year), median (IQR) 49 (33-57)
Sex, n (%)  
   Male 23 (77)
   Female 7 (23)
Body height at inclusion, cm, median (IQR) 177 (167.9-182.9)
Body weight at inclusion, kg, median (IQR) 84 (78-91)
Primary reason for MV, n (%)  
   Trauma 13 (44)
   Cardiac failure 4 (13)
   Postoperative respiratory failure 4 (13)
   Acute respiratory distress syndrome 3 (10)
   Coma/CNS disease 3 (10)
   Sepsis 2 (7)
   Pulmonary embolism 1 (3)
Tracheotomy, n (%) 7 (23)
Septic shock at inclusion, n (%) 2 (7)
Vasopressor use at inclusion, n (%) 5 (17)
MV duration before VAP onset, days, median (IQR) 9 (5-11)
Acute respiratory distress syndrome at inclusion, n (%) 5 (17)
PaO2/FIO2 ratio upon inclusion, mmHg, median (IQR) 210 (171-281)
  1. *Two of these patients were not included in the pharmacokinetic analysis because they did not received at least three full days of study medication.
  2. CNS = central nervous system; FiO2 = fraction of inspired oxygen; IQR = interquartile range; MV = mechanical ventilation; PaO2 = partial pressure of arterial oxygen; VAP = ventilator-associated pneumonia;